Linagliptin Improves Glycemic Control in Type 2 Diabetes Patients Inadequately Controlled by Metformin and Sulfonylurea without Weight Gain or Hypoglycemia

被引：0
|
作者：
Owens, David R.
Swallow, Ros
Jones, Peter
Dugi, Klaus A.
Woerle, Hans-Juergen
机构：
来源：
DIABETES | 2010年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A149 / A149
页数：1
相关论文
共 50 条
  • [41] One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes
    Hanefeld, M
    Brunetti, P
    Schernthaner, GH
    Matthews, DR
    Charbonnel, BH
    DIABETES CARE, 2004, 27 (01) : 141 - 147
  • [42] EFFECTS OF COLESEVELAM, ROSIGLITAZONE, OR SITAGLIPTIN ON GLYCEMIC CONTROL AND LIPID PROFILE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY METFORMIN MONOTHERAPY
    Rigby, Scott. P.
    Handelsman, Yehuda
    Lai, Yu-Ling
    Abby, Stacey L.
    Tao, Ben
    Jones, Michael R.
    ENDOCRINE PRACTICE, 2010, 16 (01) : 53 - 63
  • [43] Improved glycemic control with oral recombinant human insulin in patients with type 2 diabetes (T2DM) inadequately controlled on metformin
    Goldberg, Michael
    Dinh, Steve
    Castelli, Cristina
    Majuru, Shingai
    Arbit, Ehud
    DIABETES, 2007, 56 : A121 - A122
  • [44] Linagliptin monotherapy improves glycaemic control in type 2 diabetes patients for whom metformin therapy is inappropriate
    Barnett, A. H.
    Harper, R.
    Toorawa, R.
    Patel, S.
    Woerle, H. - J.
    DIABETOLOGIA, 2010, 53
  • [45] Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
    DeFronzo, Ralph A.
    Lewin, Andrew
    Patel, Sanjay
    Liu, Dacheng
    Kaste, Renee
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES CARE, 2015, 38 (03) : 384 - 393
  • [46] Linagliptin Monotherapy Improves Glycemic Control and Measures of β-cell Function in Type 2 Diabetes
    Del Prato, Stefano
    Barnett, Anthony
    Huismann, Holger
    Neubacher, Dietmar
    Woerle, Hans-Juergen
    Dugi, Klaus A.
    DIABETES, 2010, 59 : A189 - A189
  • [47] Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea
    Shin, Yujin
    Moon, Ji Hye
    Chin, Ho Jun
    Ferrannini, Ele
    Lim, Soo
    ENDOCRINOLOGY AND METABOLISM, 2020, 35 (02) : 329 - 338
  • [48] Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV
    Matthew J. Budoff
    Timothy M. E. Davis
    Alexandra G. Palmer
    Robert Frederich
    David E. Lawrence
    Jie Liu
    Ira Gantz
    Giuseppe Derosa
    Diabetes Therapy, 2021, 12 : 1279 - 1297
  • [49] Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV
    Budoff, Matthew J.
    Davis, Timothy M. E.
    Palmer, Alexandra G.
    Frederich, Robert
    Lawrence, David E.
    Liu, Jie
    Gantz, Ira
    Derosa, Giuseppe
    DIABETES THERAPY, 2021, 12 (05) : 1279 - 1297
  • [50] COMPARISON OF VILDAGLIPTIN AS AN ADD-ON THERAPY AND SULFONYLUREA DOSE-INCREASING THERAPY IN PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING METFORMIN AND SULFONYLUREA
    Hong, A. R.
    Lee, J.
    Ku, E. J.
    Hwangbo, Y.
    Kim, K. M.
    Moon, J. H.
    Choi, S. H.
    Jang, H. C.
    Lim, S.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S141 - S141
12345